Febuxostat has the efficacy of inhibiting uric acid production and is clinically used for the long-term treatment of hyperuricemia in gout, but is not recommended for the treatment of hyperuricemia without clinical symptoms. Febuxostat is a xanthine oxidase inhibitor that reduces serum uric acid concentration by inhibiting uric acid synthesis, and Febuxostat does not inhibit other enzymes involved in the synthesis and metabolism of pyrimidines and purines at conventional therapeutic concentrations, and is commonly used in the long-term treatment of gouty hyperuricemia, but it is not recommended to be used in the treatment of non-clinical symptoms of hyperuricemia. Common adverse drug reactions after febuxostat administration include abnormal liver function, arthralgia, rash and nausea. Treatment with this drug is contraindicated in patients who are using azathioprine, geranylgeranyl and in patients who are allergic to the components of the drug febuxostat. It is important to monitor blood and liver and kidney functions during the use of the drug. The drug should be used under the guidance of a physician, and it is recommended that patients go to the rheumatology and immunology departments of regular hospitals and other related departments for detailed consultation before taking the drug as prescribed.